Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.
|
| Abstract | BACKGROUND: OBJECTIVE: To determine the effect of voclosporin (VCS) treatment on quality of life in patients with psoriasis. PATIENTS AND METHODS: 451 plaque psoriasis patients with ≥ 10% body surface area involvement were randomly assigned in a double-blind fashion to 1 of 4 treatment groups (placebo, VCS 0.2 mg kg(-1) BID, VCS 0.3 mg kg(-1) BID, and VCS 0.4 mg kg(-1) BID) for up to 12 weeks of treatment. Quality of life was assessed using the Dermatology Life Quality Index (DLQI) and the Psoriasis Disability Index (PDI). RESULTS: At 12 weeks, patients treated with VCS 0.4 mg kg(-1) BID had statistically significantly more favourable assessments than placebo-treated patients in all domains of the DLQI and the PDI. Patients treated with VCS 0.3 mg kg(-1) BID had statistically significant improvements in 5 of 10 domains of the DLQI and all domains of the PDI. Patients treated with VCS 0.2 mg kg(-1) BID had statistically significant improvements in 4 of 10 domains of the DLQI and 2 of 4 domains of the PDI. CONCLUSION: Treatment with VCS 0.4 mg kg(-1) BID significantly improves the quality of life of patients with psoriasis.
|
|---|---|
| Authors | Rod Kunynetz, Wayne Carey, Richard Thomas, Darryl Toth, Ted Trafford, Ronald Vender |
| Journal | European journal of dermatology : EJD (Eur J Dermatol) 2011 Jan-Feb Vol. 21 Issue 1 Pg. 89-94 ISSN: 1167-1122 [Print] France |
| PMID | 21227890 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!